|Foundation Medicine Inc -- USA Stock|| |
USD 82.60 2.75 3.44%
Mr. Jason Ryan serves as a Chief Financial Officer, Principal Financial Officer, Principal Accounting officer of the Company. He previously served as our Senior Director, Finance from May 2011 to March 2012. Prior to joining us, Mr. Ryan led the finance and strategic planning functions of Taligen Therapeutics, Inc., which was acquired by Alexion Pharmaceuticals, Inc., from May 2009 to April 2011, Codon Devices Inc. from May 2007 to May 2009, and Genomics Collaborative, Inc., which was acquired by SeraCare Life Sciences, Inc., from September 1998 to September 2004. He began his career at Deloitte Touche
Age: 41 CFO Since 2015 CPA
Ryan holds a B.S. in economics from Bates College and an M.B.A. from Babson College, and earned a C.P.A. in Massachusetts.
Jason Ryan Latest Insider Activity
The company has Return on Asset of (52.52) %
which means that on every $100 spent on asset it lost $52.52. This is way below average. In the same way, it shows return on shareholders equity (ROE)
of (164.33) %
meaning that it generated no profit with money invested by stockholders.
The company has 60 M in debt with debt to equity (D/E) ratio of 189.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine Inc has Current Ratio of 1.82 which is typical for the industry and considered as normal.
Foundation Medicine, Inc. provides various molecular information products in the United States. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc. Foundation Medicine operates under Medical Laboratories Research classification in USA and traded on NASDAQ exchange. It employs 662 people.Foundation Medicine Inc (FMI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 662 people. Foundation Medicine is listed under Healthcare category by Fama And French industry classification.